By


Hanimune Therapeutics raises $3.3M, sets sights on first food allergy treatment product

See more here

By


Palvella Therapeutics Announces Pipeline Update on QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ Rapamycin) for Serious, Rare Genetic Skin Diseases with No FDA-approved Therapies

– Pivotal Phase 3 data for the treatment of Pachyonychia Congenita anticipated mid-2023 –

– Phase 2 data for the treatment of Microcystic Lymphatic Malformations anticipated March 2023 –

– Phase 2b data for the prevention of Basal Cell Carcinomas in patients with Gorlin Syndrome anticipated 2Q 2023 –

See more here

By


Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board

Advisory board to help guide selection of novel antibody-target pairs for ADC and T cell redirection modalities

See more here

By


Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson’s Disease

The Company was Granted Approval for an Additional 48 sites Across Five European Union Countries

Annovis Currently has 50 Clinical Trial Sites Open in the United States

See more here

By


Services for the UnderServed (S:US) Partners with Ride Health to Improve Transportation for Clients with Intellectual and Developmental Disabilities (I/DD)

See more here

By


Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses

See more here

By


iVIEW Therapeutics announces a successful pre-IND meeting with FDA and Received its Full Agreement on Development Plans for IVW-1001, a Novel Treatment for Dry Eye Disease

See more here

By


Strados Labs Forms Collaboration with Boehringer Ingelheim for its Idiopathic Pulmonary Fibrosis (IPF) Pilot Study

Starting in early 2023 the biopharmaceutical company will use the Strados RESP™ Biosensor to remotely monitor cough and crackles in patients at home.

See more here

By


Annovis Bio Announces Patient Enrollment Update For Phase 3 Study of Buntanetap for the Treatment of Parkinson’s Disease

Strong enrollment in Phase 3 trial demonstrates continued execution

Interim analysis expected in 2Q 2023

See more here

By


iVIEW announces Completion of First Patient Treatment in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis

See more here